Cutting through the noise: the handful of pricing proposals the Trump administration or Congress may enact

Scores of proposals for reducing the cost of drugs are swirling around Congress, the White House and the U.S. Department of Health and Human Services, but only a few merit attention outside the beltway.

Eliminating ideas that are unlikely to be put into effect, as well as those that will have minor impacts, yields a list of 10 initiatives that could have substantial impacts on drug companies (see Figure: “Separation of Powers”)...